REFERENCES:

1.Saroja C, Lakshmi P, Bhaskaran S. Recent trends in vaccine delivery systems: a review. Int J Pharm Investig. 2011;1(2):64–74
2.Pfattheicher S, Petersen MB, Böhm R. Information about herd immunity through vaccination and empathy promote COVID-19 vaccination intentions. Health psychology: official journal of the Division of Health Psychology, American Psychological Asso ciation. 2022;41(2):85–93. https:// doi. org/ 10. 1037/ hea00 01096.
3. Shaw AR, Feinberg MB. Vaccines. Clin Immunol 2013:1095–121
4.Kim Y-C, Park J-H, Prausnitz MR. Microneedles for drug and vac cine delivery. Adv Drug Deli Rev 2012; 64(14):1547-68; PMID:22575858; http://dx.doi.org/10.1016/j.addr.2012.04.005
5.World Health Organization. Vaccines and immunization: what is vaccination? [Internet] 2020 [updated 2021 Feb 22]. Available from: https:// www. who. Int/ news- room/q- a- detail/vaccination- and- immunization- what- is- vaccination. Accessed 1 June 2021.
6.Kang SM, Song JM, Kim YC. Microneedle and mucosal delivery of influenza vaccines. Expert Rev Vaccines. 2012;11(5):547–560. [ second pdf].
7.Gerstel MS, Place VA, inventors. Drug delivery device. United States patent US3964482. June 22, 1976.
8. Giudice EL, Campbell JD. Needle-free vaccine delivery. Adv Drug Deliv Rev 2006; 58(1): p. 68-89; PMID:16564111; http://dx.doi.org/ 10.1016/j.addr.2005.12.003
9. Moga KA, Bickford LR, Geil RD, Dunn SS, Pandya AA, Wang Y, et al. Rapidly dissolvable microneedle patches via a highly scalable and reproducible soft lithography approach. Advanced materials (Deerfield Beach, Fla). 2013;25(36);5060-6.
10. Hirobe S, Azukizawa H, Matsuo K, Zhai Y, Quan Y-S, Kamiy ama F, et al. Development and clinical study of a self-dissolving microneedle patch for a transcutaneous immunization device. Pharm Res. 2013;30(10):2664–74. 13. Rodgers AM, McCrudden MTC, Vincente-Perez EM, Dubois AV, Ingram RJ, Larrañeta E, et al. Design and characterisation of a dissolving microneedle patch for intradermal vaccination with heat -inactivated bacteria: a proof of concept study. Int J Pharm. 2018;549(1–2):87–95.
11. Rodgers AM, McCrudden MTC, Vincente-Perez EM, Dubois AV, Ingram RJ, Larrañeta E, et al. Design and characterisation of a dissolving microneedle patch for intradermal vaccination with heat-inactivated bacteria: a proof of concept study. Int J Pharm. 2018;549(1–2):87–95.
12..M, Priester MI, Romeijn S, Nejadnik MR, Mönkäre J, O’Mahony C, et al. Hyaluronan-based dissolving microneedles with high antigen content for intradermal vaccination: formulation, physicochemical characterization, and immunogenicity assessment. Eur J Pharm Biopharm. 2019;134:49–59.
13.Kim E, Erdos G, Huang S, Kenniston TW, Balmert SC, Carey CD, et al. Microneedle array delivered recombinant coronavirus vaccines: immunogenicity and rapid translational development. EBioMedicine. 2020;55:102743.
14.Leone M, Priester MI, Romeijn S, Nejadnik MR, Mönkäre J, O’Mahony C, et al. Hyaluronan-based dissolving microneedles with high antigen content for intradermal vaccination: formulation, physicochemical characterization and immunogenicity assessment. Eur J Pharm Biopharm. 2019;134:49–59.
15.Caudill C, Perry JL, Iliadis K, Tessema AT, Lee BJ, Mecham BS, et al. Transdermal vaccination via 3D-printed microneedles induces potent humoral and cellular immunity. Proceedings of the National Academy of Sciences. 2021;118(39):e2102595118.
16.O’Shea J, Prausnitz MR, Rouphael N. Dissolvable microneedle patches to enable increased access to vaccines against SARS CoV-2 and future pandemic outbreaks. Vaccines. 2021;9(4).
17.CFR—Code of Federal Regulations Title 21. Available online: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=177&showFR=1 (accessed on 29 March 2021).
18. Jung, J.H.; Jin, S.G. Microneedle for Transdermal Drug Delivery: Current Trends and Fabrication. J. Pharm. Investig. 2021, 51, 503–517. [Google Scholar] [CrossRef]
19. Mansoor, I.; Eassa, H.A.; Mohammed, K.H.A.; Abd El-Fattah, M.A.; Abdo, M.H.; Rashad, E.; Eassa, H.A.; Saleh, A.; Amin, O.M.; Nounou, M.I.; et al. Microneedle-Based Vaccine Delivery: Review of an Emerging Technology. AAPS PharmSciTech 2022, 23, 103. [Google Scholar] [CrossRef]
20. Ai-Kasasbeh, R.; Brady, A.J.; Courtenay, A.J.; Larrañeta, E.; McCrudden, M.T.C.; O’Kane, D.; Liggett, S.; Donnelly, R.F. Evaluation of the Clinical Impact of Repeat Application of Hydrogel-Forming Microneedle Array Patches. Drug Deliv. Transl. Res. 2020, 10, 690–705. [Google Scholar] [CrossRef] [PubMed].
21.Ahmed Saeed Al-Japairai, K.; Mahmood, S.; Hamed Almurisi, S.; Reddy Venugopal, J.; Rebhi Hilles, A.; Azmana, M.; Raman, S. Current Trends in Polymer Microneedle for Transdermal Drug Delivery. Int. J. Pharm. 2020, 587, 119673. [Google Scholar] [CrossRef]
22.Wang, P.M.; Cornwell, M.; Hill, J.; Prausnitz, M.R. Precise Microinjection into Skin Using Hollow Microneedles. J. Investig. Dermatol. 2006, 126, 1080–1087. [Google Scholar] [CrossRef]
23. van der Maaden, K.; Jiskoot, W.; Bouwstra, J. Microneedle Technologies for (Trans)Dermal Drug and Vaccine Delivery. J. Control. Release 2012, 161, 645–655. [Google Scholar] [CrossRef] [PubMed].
24.Ogai, N.; Nonaka, I.; Toda, Y.; Ono, T.; Minegishi, S.; Inou, A.; Hachiya, M.; Fukamizu, H. Enhanced Immunity in Intradermal Vaccination by Novel Hollow Microneedles. Skin Res. Technol. 2018, 24, 630–635. [Google Scholar] [CrossRef] [PubMed].
25.Leone, M.; Romeijn, S.; Du, G.; Le Dévédec, S.E.; Vrieling, H.; O’Mahony, C.; Bouwstra, J.A.; Kersten, G. Diphtheria Toxoid Dissolving Microneedle Vaccination: Adjuvant Screening and Effect of Repeated-Fractional Dose Administration. Int. J. Pharm. 2020, 580, 119182. [Google Scholar] [CrossRef] [PubMed].
26.Tucak, A.; Sirbubalo, M.; Hindija, L.; Rahić, O.; Hadžiabdić, J.; Muhamedagić, K.; Čekić, A.; Vranić, E. Microneedles: Characteristics, Materials, Production Methods and Commercial Development. Micromachines 2020, 11, 961. [Google Scholar] [CrossRef] [PubMed].
27.Ai, X.; Yang, J.; Liu, Z.; Guo, T.; Feng, N. Recent Progress of Microneedles in Transdermal Immunotherapy: A Review. Int. J. Pharm. 2024, 662, 124481. [Google Scholar] [CrossRef].
28.Choo, J.J.Y.; Vet, L.J.; McMillan, C.L.D.; Harrison, J.J.; Scott, C.A.P.; Depelsenaire, A.C.I.; Fernando, G.J.P.; Watterson, D.; Hall, R.A.; Young, P.R.; et al. A Chimeric Dengue Virus Vaccine Candidate Delivered by High Density Microarray Patches Protects against Infection in Mice. npj Vaccines 2021, 6, 66. [Google Scholar] [CrossRef] [PubMed].
29.vander Straeten, A.; Sarmadi, M.; Daristotle, J.L.; Kanelli, M.; Tostanoski, L.H.; Collins, J.; Pardeshi, A.; Han, J.; Varshney, D.; Eshaghi, B.; et al. A Microneedle Vaccine Printer for Thermostable COVID-19 mRNA Vaccines. Nat. Biotechnol. 2024, 42, 510–517. [Google Scholar] [CrossRef].
30.McMillan, C.L.D.; Choo, J.J.Y.; Idris, A.; Supramaniam, A.; Modhiran, N.; Amarilla, A.A.; Isaacs, A.; Cheung, S.T.M.; Liang, B.; Bielefeldt-Ohmann, H.; et al. Complete Protection by a Single-Dose Skin Patch–Delivered SARS-CoV-2 Spike Vaccine. Sci. Adv. 2021, 7, eabj8065. [Google Scholar] [CrossRef].
31.Wan, Y.; Gupta, V.; Bird, C.; Pullagurla, S.R.; Fahey, P.; Forster, A.; Volkin, D.B.; Joshi, S.B. Formulation Development and Improved Stability of a Combination Measles and Rubella Live-Viral Vaccine Dried for Use in the NanopatchTM Microneedle Delivery System. Hum. Vaccines Immunother. 2021, 17, 2501–2516. [Google Scholar] [CrossRef] [PubMed].
32.Forster, A.H.; Witham, K.; Depelsenaire, A.C.I.; Veitch, M.; Wells, J.W.; Wheatley, A.; Pryor, M.; Lickliter, J.D.; Francis, B.; Rockman, S.; et al. Safety, Tolerability, and Immunogenicity of Influenza Vaccination with a High-Density Microarray Patch: Results from a Randomized, Controlled Phase I Clinical Trial. PLoS Med. 2020, 17, e1003024. [Google Scholar] [CrossRef] [PubMed].
33.Li, E.; Balmert, S.C.; Sumpter, T.L.; Carey, C.D.; Erdos, G.; Falo, L.D. Microarray Patches Enable the Development of Skin-Targeted Vaccines against COVID-19. Adv. Drug Deliv. Rev. 2021, 171, 164–186. [Google Scholar] [CrossRef]
34.Li, J.; Zeng, M.; Shan, H.; Tong, C. Microneedle Patches as Drug and Vaccine Delivery Platform. Curr. Med. Chem. 2017, 24, 2413–2422. [Google Scholar] [CrossRef] [PubMed]
35.Duong, H.T.T.; Yin, Y.; Thambi, T.; Nguyen, T.L.; Giang Phan, V.H.; Lee, M.S.; Lee, J.E.; Kim, J.; Jeong, J.H.; Lee, D.S. Smart Vaccine Delivery Based on Microneedle Arrays Decorated with Ultra-pH-Responsive Copolymers for Cancer Immunotherapy. Biomaterials 2018, 185, 13–24. [Google Scholar] [CrossRef]
36.He, Y.; Hong, C.; Li, J.; Howard, M.T.; Li, Y.; Turvey, M. Kim, Y.-C.; Quan, F.-S.; Compans, R.W.; Kang, S.-M.; Prausnitz, M.R. Formulation and Coating of Microneedles with Inactivated Influenza Virus to Improve Vaccine Stability and Immunogenicity. J. Control. Release 2010, 142, 187–195. [Google Scholar] [PubMed]
37.Kim, Y.-C.; Quan, F.-S.; Compans, R.W.; Kang, S.-M.; Prausnitz, M.R. Formulation and Coating of Microneedles with Inactivated Influenza Virus to Improve Vaccine Stability and Immunogenicity. J. Control. Release 2010, 142, 187–195. [Google Scholar] [PubMed].
38.Fernando, G.J.; Hickling, J.; Flores, C.M.J.; Griffin, P.; Anderson, C.D.; Skinner, S.R.; Davies, C.; Witham, K.; Pryor, M.; Bodle, J. Safety, Tolerability, Acceptability and Immunogenicity of an Influenza Vaccine Delivered to Human Skin by a Novel High-Density Microprojection Array Patch (NanopatchTM). Vaccine 2018, 36, 3779–3788. [Google Scholar] [CrossRef] [PubMed]
39.Wendorf, J.R.; Ghartey-Tagoe, E.B.; Williams, S.C.; Enioutina, E.; Singh, P.; Cleary, G.W. Transdermal Delivery of Macromolecules Using Solid-State Biodegradable Microstructures. Pharm. Res. 2010, 28, 22–30. [Google Scholar] [CrossRef]
41.McNamee, M.; Wong, S.; Guy, O.; Sharma, S. Microneedle Technology for Potential SARS-CoV-2 Vaccine Delivery. Expert Opin. Drug Deliv. 2023, 20, 799–814. [Google Scholar] [CrossRef]
42.Yang, J.; Liu, X.; Fu, Y.; Song, Y. Recent Advances of Microneedles for Biomedical Applications: Drug Delivery and Beyond. Acta Pharm. Sin. B 2019, 9, 469–483. [Google Scholar] [CrossRef].
43.Flynn, O.; Dillane, K.; Lanza, J.S.; Marshall, J.M.; Jin, J.; Silk, S.E.; Draper, S.J.; Moore, A.C. Low Adenovirus Vaccine Doses Administered to Skin Using Microneedle Patches Induce Better Functional Antibody Immunogenicity as Compared to Systemic Injection. Vaccines 2021, 9, 299. [Google Scholar] [CrossRef]
44.Himawan, A.; Vora, L.K.; Permana, A.D.; Sudir, S.; Nurdin, A.R.; Nislawati, R.; Hasyim, R.; Scott, C.J.; Donnelly, R.F. Where Microneedle Meets Biomarkers: Futuristic Application for Diagnosing and Monitoring Localized External Organ Diseases. Adv. Healthc. Mater. 2023, 12, 2202066. [Google Scholar] [CrossRef] [PubMed]
45.Larrañeta, E.; Lutton, R.E.; Woolfson, A.D.; Donnelly, R.F. Microneedle arrays as transdermal and intradermal drug delivery systems: Materials science, manufacture and commercial development. Mater. Sci. Eng. R Rep. 2016, 104, 1–32. [Google Scholar] [CrossRef] [Green Version]
46.Lambert, P.H.; Laurent, P.E. Intradermal vaccine delivery: Will new delivery systems transform vaccine administration? Vaccine 2008, 26, 3197–3208. [Google Scholar] [CrossRef]
47. Excler, J.-L.; Privor-Dumm, L.; Kim, J.H. Supply and Delivery of Vaccines for Global Health. Curr. Opin. Immunol. 2021, 71, 13–20. [Google Scholar] [CrossRef]
48. Privor-Dumm, L.; Excler, J.-L.; Gilbert, S.; Karim, S.S.A.; Hotez, P.J.; Thompson, D.; Kim, J.H. Vaccine Access, Equity and Justice: COVID-19 Vaccines and Vaccination. BMJ Glob. Health 2023, 8, e011881. [Google Scholar] [CrossRef]
49. Kim, Y.-C.; Prausnitz, M.R. Enabling Skin Vaccination Using New Delivery Technologies. Drug Deliv. Transl. Res. 2011, 1, 7–12. [Google Scholar] [CrossRef] [PubMed]
50.Kommareddy, S.; Baudner, B.C.; Oh, S.; Kwon, S.; Singh, M.; O’Hagan, D.T. Dissolvable Microneedle Patches for the Delivery of Cell-Culture-Derived Influenza Vaccine Antigens. J. Pharm. Sci. 2012, 101, 1021–1027. [Google Scholar] [CrossRef] [PubMed]
51.Sullivan, S.P.; Koutsonanos, D.G.; Del Pilar Martin, M.; Lee, J.W.; Zarnitsyn, V.; Choi, S.-O.; Murthy, N.; Compans, R.W.; Skountzou, I.; Prausnitz, M.R. Dissolving Polymer Microneedle Patches for Influenza Vaccination. Nat. Med. 2010, 16, 915–920. [Google Scholar] [CrossRef]
52. Arnou, R.; Eavis, P.; De Juanes Pardo, J.-R.; Ambrozaitis, A.; Kazek, M.-P.; Weber, F. Immunogenicity, Large Scale Safety and Lot Consistency of an Intradermal Influenza Vaccine in Adults Aged 18–60 Years: Randomized, Controlled, Phase III Trial. Hum. Vaccin. 2010, 6, 346–354. [Google Scholar] [CrossRef]
53.Van Damme, P.; Oosterhuis-Kafeja, F.; Van der Wielen, M.; Almagor, Y.; Sharon, O.; Levin, Y. Safety and Efficacy of a Novel Microneedle Device for Dose Sparing Intradermal Influenza Vaccination in Healthy Adults. Vaccine 2009, 27, 454–459. [Google Scholar] [CrossRef]
54.Leone, M.; Priester, M.I.; Romeijn, S.; Nejadnik, M.R.; Mönkäre, J.; O’Mahony, C.; Jiskoot, W.; Kersten, G.; Bouwstra, J.A. Hyaluronan-Based Dissolving Microneedles with High Antigen Content for Intradermal Vaccination: Formulation, Physicochemical Characterization and Immunogenicity Assessment. Eur. J. Pharm. Biopharm. 2019, 134, 49–59. [Google Scholar] [CrossRef]
55.Caudill, C.; Perry, J.L.; Iliadis, K.; Tessema, A.T.; Lee, B.J.; Mecham, B.S.; Tian, S.; DeSimone, J.M. Transdermal Vaccination via 3D-Printed Microneedles Induces Potent Humoral and Cellular Immunity. Proc. Natl. Acad. Sci. USA 2021, 118, e2102595118. [Google Scholar] [CrossRef]
56.vander Straeten, A.; Sarmadi, M.; Daristotle, J.L.; Kanelli, M.; Tostanoski, L.H.; Collins, J.; Pardeshi, A.; Han, J.; Varshney, D.; Eshaghi, B.; et al. A Microneedle Vaccine Printer for Thermostable COVID-19 mRNA Vaccines. Nat. Biotechnol. 2024, 42, 510–517. [Google Scholar] [CrossRef]
57. Korkmaz, E.; Balmert, S.C.; Sumpter, T.L.; Carey, C.D.; Erdos, G.; Falo, L.D. Microarray Patches Enable the Development of Skin-Targeted Vaccines against COVID-19. Adv. Drug Deliv. Rev. 2021, 171, 164–186. [Google Scholar] [CrossRef]
58.Kirkby, M.; Hutton, A.R.; Donnelly, R.F. Microneedle Mediated Transdermal Delivery of Protein, Peptide and Antibody Based Therapeutics: Current Status and Future Considerations. Pharm. Res. 2020, 37, 117. [Google Scholar] [CrossRef]
59. Korkmaz, E.; Balmert, S.C.; Carey, C.D.; Erdos, G.; Louis D Falo, J. Emerging Skin-Targeted Drug Delivery Strategies to Engineer Immunity: A Focus on Infectious Diseases. Expert Opin. Drug Deliv. 2020, 18, 151. [Google Scholar] [CrossRef]
60.Yin Y, Su W, Zhang J, Huang W, Li X, Ma H, et al. Separable microneedle patch to protect and deliver DNA nanovaccines Against COVID-19. ACS Nano. 2021;15(9):14347–14359. doi: 10.1021/acsnano.1c03252. [DOI] [PubMed] [Google Scholar
61.Alarcon JB, Hartley AW, Harvey NG, Mikszta JA. Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines. Clin Vaccine Immunol. 2007;14(4):375–381. doi: 10.1128/CVI.00387-06. [DOI] [PMC free article] [PubMed] [Google Scholar.
62.Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. Microneedle-based vaccines. Curr Top Microbiol Immunol. 2009;333:369–393. doi: 10.1007/978-3-540-92165-3_18. [DOI] [PMC free article] [PubMed] [Google Scholar]
63.Bariya SH, Gohel MC, Mehta TA, Sharma OP. Microneedles: an emerging transdermal drug delivery system. J Pharm Pharmacol. 2012;64(1):11–29. doi: 10.1111/j.2042-7158.2011.01369.x. [DOI] [PubMed] [Google Scholar]
64.Prausnitz, M.R. et al. (2009) Microneedle-based vaccines. Curr. Top. Microbiol. Immunol. 333, 369–393
65.Leroux-Roels, I. et al. (2008) Seasonal influenza vaccine delivered by intradermal microinjection: a randomized controlled safety and immunogenicity trial in adults. Vaccine 26, 6614–6619
66.Aimanianda,V.etal.(2009)Novel cellular and molecular mechanismsofinduction of immune responses by aluminum adjuvants. Trends Pharmacol. Sci. 30, 287–295